SREBF1 and chronic kidney disease: De Macedo et al. (2015) showed that activation of ACE2 using diminazene aceturate had a significant effect on lipogenesis. In vitro, we found that SREBP1 expression is also upregulated in lung epithelial cells of obese subjects compared to non-obese subjects. In studies in chronic kidney disease it has been shown that angiotensin II activates SREBP1 which mediates angiotensin II–induced profibrogenic responses (Wang T.N. et al., 2015).